BSX Stock Analysis: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$45.60
1.27 (2.86%)
▲
5d:
-2.48%
30d:
-20.21%
90d:
-34.43%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 22, 2026
27d
Smart Money Accumulation
None View Scanner →
Strength: 10.0/10
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BSX appears deeply undervalued. Market expects -14.6% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: BSX appears deeply undervalued. Market expects -14.6% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$104.46
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$64.86
29.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $45.60, which is considered oversold relative to its 30-day fair value range of $45.65 to $54.13. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.2) compared to its historical average (19.7). Remarkably, the market is currently pricing in an annual earnings decline of 14.6% over the next few years. This pessimistic expectation contrasts with the company's recent 100% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a strong downtrend. Immediate support is located at $44.05, while resistance sits at $49.86.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $76.48 (+67.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BSX is in a strong downtrend. Immediate support is located at $44.05, while resistance sits at $49.86.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $76.48 (+67.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$45.65 -
$54.13
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.7% below Wall St target ($76.48)
Trading Range Analysis
30-Day Trading Range
$45.65 -
$54.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$44.05
Resistance Level
$49.86
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.25
Wall Street Target
$76.48
(+67.7%)
Revenue Growth (YoY)
11.6%
Earnings Growth (YoY)
100.0%
Profit Margin
17.3%
Valuation Discount vs History
-14.6% cheaper
PE vs Historical
12.3 vs 19.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.6%
(market-implied from PE analysis)
1-Year Target
$41.04
(-10%)
2-Year Target
$36.94
(-19%)
3-Year Target
$33.24
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→20)
$53.48
(+17%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 10.7%)
$110.01
(+141%)
Base:
(SPY PE: 12.2, Growth: 10.7%)
$61.85
(+36%)
Bear:
(PE: 10.4, Growth: 10.7%)
$52.57
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 18.55 | Current EPS (TTM): $2.39
Bull Case
$75.98
(+67%)
Analyst growth 55.8%, PE expands to 20.4
Base Case
$69.07
(+52%)
Market implied 55.8%, PE stable at 18.6
Bear Case
$30.14
(-34%)
Severe decline -20.0%, PE contracts to 15.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.2 to 19.7
Stabilization Target:
$73.36
(+60.9%)
PE Expansion Potential:
+60.9%
Share & Embed Analysis
Last updated: June 24, 2026 12:34 AM ET
Data refreshes hourly during market hours. Next update: 1:34 AM
Data refreshes hourly during market hours. Next update: 1:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
6
Buys
6
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-30
Ro Khanna
SELL
2026-03-23
Ro Khanna
SELL
2026-02-24
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 61 BUY |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
